Innovative Lidocaine Infusion Shows Promise for Refractory Migraines
- MigraineMind
- Nov 5, 2025
- 1 min read
Research Summary
A study published in the Journal of Neuroimaging explored the effects of middle meningeal artery lidocaine infusion on patients with refractory migraines. The researchers evaluated the treatment's efficacy over a 3-month period using the Migraine Disability Assessment (MIDAS) score. Eight patients participated, and results showed significant improvement in their MIDAS scores from 86.3 to 23.5, with 62.5% experiencing a 50% reduction in disability. Half of the participants achieved "no disability" status, and most discontinued opioid medication. The study confirmed a sustained improvement in 50% of patients and reported no adverse events, highlighting the potential benefits of this treatment approach.
Study Details
👥 Research Team: Fakih R et al.
📚 Published In: J Neuroimaging
📅 Publication Date: 2025 Nov-Dec
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.